Skip to main content
SpringerLink
Log in

Postoperative Crohn’s Disease

  • Chapter
  • First Online:
Biomarkers in Inflammatory Bowel Diseases

Abstract

This chapter will cover prognostic and predictive biomarkers that have been identified in association with postoperative recurrence of Crohn’s disease. It will discuss the optimal management of Crohn’s disease following resectional surgery with reference to the natural history of Crohn’s disease after surgery, risk factors for earlier postoperative recurrence, diagnosis and monitoring of recurrence and therapeutic strategies to address prevention of recurrence. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011;60:1178–81.

    Article  Google Scholar 

  2. Farmer RG, Hawk WA, Turnbull RB. Efficacy and complications of surgery for Crohn’s disease. Gastroenterol Hepatol. 2010;6(9):587–96.

    Google Scholar 

  3. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331–5.

    Article  CAS  Google Scholar 

  4. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–72.

    Article  CAS  Google Scholar 

  5. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.

    Article  CAS  Google Scholar 

  6. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231:38–45.

    Article  CAS  Google Scholar 

  7. D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262.

    Article  Google Scholar 

  8. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338(8770):771.

    Article  CAS  Google Scholar 

  9. De Cruz P, Kamm MA, Prideaux L, et al. Postoperative recurrent luminal Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2012;18:758–77.

    Article  Google Scholar 

  10. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17.

    Article  Google Scholar 

  11. Simillis C, Yamamoto T, Reese GE, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn’s disease. Am J Gastroenterol. 2008;103:196–205.

    Article  Google Scholar 

  12. Rutgeerts P, Van Assche G. What is the role of endoscopy in the postoperative management of Crohn’s disease? Inflamm Bowel Dis. 2008;14(suppl 2):S179–80.

    Article  Google Scholar 

  13. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7(4):460–5.

    Article  CAS  Google Scholar 

  14. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56–66.

    Article  CAS  Google Scholar 

  15. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746–54.

    Article  Google Scholar 

  16. Wright E, De Cruz P, Gearry R, et al. Fecal biomarkers in the diagnosis and monitoring of Crohn’s disease. Inflamm Bowel Dis. 2014;20:1668–77.

    Article  Google Scholar 

  17. Steinbakk M, Naess-Andresen CF, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763–5.

    Article  CAS  Google Scholar 

  18. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–8.

    Article  CAS  Google Scholar 

  19. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–47.

    Article  CAS  Google Scholar 

  20. Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18(7):1340–55.

    Article  Google Scholar 

  21. Hamilton AL, Kamm MA, De Cruz P, et al. Serologic antibodies in relation to outcome in postoperative Crohn’s disease. J Gastroenterol Hepatol. 2017;32(6):1195–203.

    Article  CAS  Google Scholar 

  22. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–9.

    Article  CAS  Google Scholar 

  23. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.

    Article  CAS  Google Scholar 

  24. D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–9.

    Article  Google Scholar 

  25. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–61.

    Article  CAS  Google Scholar 

  26. Doherty GA, Bennett GC, Cheifetz AS, et al. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease. Aliment Pharmacol Ther. 2010;31:802–9.

    CAS  PubMed  Google Scholar 

  27. Neurath M. Thiopurines in IBD. Gastroenterol Heaptol. 2010;6(7):435–6.

    Google Scholar 

  28. Mowat C, Arnott I, Cahill A, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2016;1(4):273–82.

    Article  Google Scholar 

  29. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50.

    Article  CAS  Google Scholar 

  30. De Cruz P, Kamm MA, Hamilton AL, et al. Adalimumab prevents post-operative Crohn’s disease recurrence, and is superior to thiopurines: early results from the POCER study. Gastroenterology. 2012;142:S–212.

    Google Scholar 

  31. Regeuiro M, Feagan B, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150(7):1568–78.

    Article  Google Scholar 

  32. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;38599976:1406–17.

    Article  Google Scholar 

  33. De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients – a POCER study analysis. Aliment Pharmacol Ther. 2015;42(7):867–79.

    Article  Google Scholar 

  34. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02834754, A randomised, double-blind, placebo controlled study of vedolizumab for the prevention of post-operative Crohn’s disease recurrence (Vedo Post-op); 2016 [cited 2017 Oct 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02834754.

  35. Saffouri E, Kemp L, Muir A, et al. PTU-140 Vedolizumab is an effective therapy in postoperative ileal crohns following loss of response to anti-tnf. Gut. 2017;66:A119–20.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia

    Kurvi Patwala & Peter De Cruz

  2. Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz

Authors
  1. Kurvi Patwala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter De Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Vincent’s Hospital, The University of Melbourne, Melbourne, VIC, Australia

    Nik Sheng Ding

  2. Austin Health, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patwala, K., De Cruz, P. (2019). Postoperative Crohn’s Disease. In: Sheng Ding, N., De Cruz, P. (eds) Biomarkers in Inflammatory Bowel Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-11446-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11446-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11445-9

  • Online ISBN: 978-3-030-11446-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation